The Swedish BioFINDER Study

The BioFINDER studies are independent and non-overlapping studies that have been initiated with the overarching aims to discover key mechanisms in Alzheimer’s disease, Parkinson’s disease and other neurodegenerative disorders. These studies are designed to develop early and accurate diagnostic tests, identify novel treatment targets and help to understand the links between different pathologies and clinical symptoms.

BioFINDER
One

The first BioFINDER study, launched in 2008, focusing on the early stages of Alzheimer’s and Parkinson’s diseases and related disorders. It includes longitudinal assessments over a period of 6-10 years.

BioFINDER
Two

The second BioFINDER study, launched in 2017, is more comprehensive than BioFINDER One. It includes a larger number of study participants and cutting-edge brain imaging such as tau-PET in all study partcipants.

BioFINDER
Sleep

The BioFINDER Sleep study targeting prodromal Parkinson’s disease was initiated in 2021. It encompasses individuals with REM-sleep behavior disorder and those in the early stages of Parkinson’s disease.

BioFINDER
Preclinical AD

The study, launched in 2022, screens a general population with a blood test to detect preclinical (pre-symptomatic) Alzheimer’s disease. Its goals are to deepen our understanding of the initial stages of the disease and to optimize future primary and secondary prevention trials.

BioFINDER
Primary Care

This BioFINDER study was launched in 2020. It includes diverse patient populations with cognitive symptoms at different primary care centers. The main aim is to improve the diagnostic and prognostic work-up in primary care of neurocognitive disorders using blood biomarkers and brief cognitive tests.

BioFINDER
Memory Clinic

This BioFINDER study, launched in 2023, is complementary to the BioFINDER Primary Care study, but targets a Memory clinic population in a secondary care setting.

News articles

  • Key Milestones in Alzheimer’s Disease Research

    In the article “The History of Alzheimer’s Disease”, the editors of Nature journals share their insights on this topic....

    Read more...

  • Groundbreaking Alzheimer’s blood test proves highly effective in primary healthcare

    A commercially available blood test has now been trialled in routine healthcare. “The blood test showed about 90% reliability...

    Read more...
More news...

X posts

More posts...